Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
申请人:Danysz Wojciech
公开号:US20080039458A1
公开(公告)日:2008-02-14
Substituted pyrazolopyrimidine derivatives of formula (I)
wherein
Y
1
, Y
2
, Y
3
, Y
4
represent N or C—, whereby at least two of the groups Y
1
to Y
4
represent a carbon atom, R
1
represents chloro or bromo,
R
2
to R
7
represent e.g. hydrogen, methyl or ethyl; and
R
10
and R
11
independently represent e.g. hydrogen or C
1
-C
6
alkyl, are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
Substituted pyrazolo[1,5-A]pyrimidines as metabotropic glutamate receptor modulators
申请人:MERZ PHARMA GmbH & Co. KGaA
公开号:US07985753B2
公开(公告)日:2011-07-26
Substituted pyrazolopyrimidine derivatives of formula (I)
wherein
Y1, Y2, Y3, Y4 represent N or C—, whereby at least two of the groups Y1 to Y4 represent a carbon atom, R1 represents chloro or bromo,
R2 to R7 represent e.g. hydrogen, methyl or ethyl; and
R10 and R11 independently represent e.g. hydrogen or C1-C6alkyl,
are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
Substituted pyrazolopyrimidine derivatives of formula (I)
wherein
Y
1
, Y
2
, Y
3
, Y
4
represent N or C—, whereby at least two of the groups Y
1
to Y
4
represent a carbon atom, R
1
represents chloro or bromo,
R
2
to R7 represent e.g. hydrogen, methyl or ethyl; and
R
10
and R
11
independently represent e.g. hydrogen or C
1
-C
6
alkyl,
are potent mGluR5 modulators and are useful for the prevention of acute and chronic neurological disorders.
6-halo-pyrazolo[1,5-a]pyridines, a process for their preparation and their use as metabotropic glutamate receptor (mGluR) modulators
申请人:Merz Pharma GmbH & Co. KGaA
公开号:EP2090576A1
公开(公告)日:2009-08-19
The invention relates to 6-halo-pyrazolo[1,5-a]pyridines of formula (I) as well as their pharmaceutically acceptable salts. The invention further relates to a process for the preparation of such compounds. The compounds of the invention are mGluR5 modulators and are therefore useful for the control and prevention of acute and/or chronic neurological disorders.
wherein A represents -NR3R4
with R3 and R4 as described herein.